Compare Cassava Sciences Inc (FLNA) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kinross Gold Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Kinross Gold Corporation trades at $23 (market cap $27.94B). The key difference: Kinross Gold Corporation is far larger — about 525.8× Cassava Sciences Inc's market cap, and Kinross Gold Corporation pays a 0.61% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KGC | |
|---|---|---|
Market Cap | $53.14M | $27.94B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $38.06 |
52-Week Low | $1.09 | $15.33 |
Enterprise Value | -$33.43M | $26.49B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Kinross Gold (KGC) trades at $23.91, up 1.83% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals, with Q1 2026 EPS of $0.71 beating expectations and robust profitability margins. Revenue grew to $7.05 billion in 2025, with net income reaching $2.39 billion. Recent news highlights exploration updates and Q2 2026 results due July 29, 2026.
KGC presents a compelling value with a P/E of 10.07 and consensus price target of $37.20, implying significant upside. Strengths include strong cash flow growth and a healthy balance sheet. Risks involve potential margin pressure from rising costs and gold price volatility. Analyst sentiment is bullish with 59% buy ratings, supporting a positive outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
